2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5615 External validation and component-wise evaluation of IPSS-m-evo in an independent cohort of patients with myelodysplastic neoplasms

Yudi Zhang, MD, Wei Wang, PhD2, Xinping Zhou3, Liya Ma4, Yingwan Luo, MD, PhD5, Lingxu Jiang, MD6, Hongyan Tong, MD, PhD7
1 the First Affiliated Hospital of Zhejiang University, Hangzhou, China
2 the First Affiliated Hospital of Zhejiang University, Hangzhou, China
3 the First Affiliated Hospital of Zhejiang University, Hangzhou, China
4 the First Affiliated Hospital of Zhejiang University, Hangzhou, China
5 the First Affiliated Hospital of Zhejiang University, Hangzhou, China
6 the First Affiliated Hospital of Zhejiang University, Hangzhou, China
7 the First Affiliated Hospital of Zhejiang University, Hangzhou, China

Introduction

IPSS-M-Evo was recently developed by adding age and evolution-informed molecular features to the IPSS-M framework. Its incremental value over IPSS-M in Asian patients with myelodysplastic neoplasms (MDS), and the relative contributions of its added components, remain uncertain. We compared the prognostic performance of IPSS-R, IPSS-M, and IPSS-M-Evo for overall survival (OS) and leukemia-free survival (LFS), evaluated reclassification from IPSS-M to IPSS-M-Evo, and assessed individual IPSS-M-Evo components.

 

Methods

We retrospectively included 666 adults with newly diagnosed MDS treated at the First Affiliated Hospital of Zhejiang University between November 2018 and December 2025. Targeted sequencing used a 96-gene panel. GNB1, an IPSS-M residual gene, was not covered and was treated as missing in IPSS-M calculations; all other required clinical, cytogenetic, and molecular variables were available. OS and LFS were estimated using Kaplan–Meier methods and analyzed using Cox regression. Discrimination was compared using Harrell C-indices with 95% confidence intervals and paired bootstrap tests, with Holm adjustment for five prespecified comparisons per endpoint. Reclassification from IPSS-M to IPSS-M-Evo was evaluated using a 6×6 transition matrix. Component-wise analyses assessed the incremental contributions of age and the combined five-variable evolution-informed molecular component.

 

Results

The median age was 63 years (interquartile range, 55–70), and 64% of patients were male. After a median follow-up of 30.6 months, 272 (41%) patients died and 97 (14.6%) progressed to acute myeloid leukemia. The most frequent mutations were TP53 (25.7%), ASXL1 (24.6%), TET2 (17.9%), U2AF1 (14.3%), RUNX1 (13.2%), DNMT3A (12.5%), and SF3B1 (10.5%). At least one evolution-informed molecular variable was detected in 21 (3.2%) patients, including ASXL1→KRAS in 4 (0.6%), SRSF2→NRAS in 2 (0.3%), NRAS/RUNX1 co-occurrence in 7 (1.1%), ATRX in 1 (0.15%), and JAK2 in 8 (1.2%). IPSS-R, IPSS-M, and IPSS-M-Evo each significantly stratified OS and LFS (all log-rank P < 0.001). Their Harrell C-indices were 0.726, 0.734, and 0.755 for OS and 0.709, 0.721, and 0.736 for LFS, respectively. Compared with IPSS-R, IPSS-M-Evo increased the C-index by 0.029 for OS (95% CI, 0.006–0.052; P = 0.039) and 0.026 for LFS (95% CI, 0.005–0.050; P = 0.048); corresponding differences versus IPSS-M were 0.021 (95% CI, 0.012–0.030; P = 0.005) and 0.015 (95% CI, 0.006–0.025; P = 0.005), respectively (all P values Holm-adjusted).

IPSS-M-Evo reclassified 58.6% of patients relative to IPSS-M: 1.8% were upgraded, 56.8% downgraded, and 7.2% shifted by at least two categories. Reclassification was most frequent in the moderate-high, high, and very-high groups (74.7%, 61.4%, and 58.5%, respectively). Among reclassified patients, IPSS-M-Evo provided additional prognostic separation, most clearly within the original high and very-high groups. Outcomes after upgrading could not be reliably assessed because only 12 patients were upgraded and two events occurred; downgraded patients had superior OS and LFS within the original high and very-high groups compared with those remaining in their original categories.

Age yielded the largest C-index improvement for OS and LFS (ΔC-index, 0.017 and 0.011), particularly for OS. After Holm adjustment, the age increment remained significant for OS (P = 0.004) but not LFS (P = 0.054); the combined molecular component was significant for LFS (ΔC-index, 0.004; P = 0.015) but not OS (ΔC-index, 0.003; P = 0.054).

 

Conclusion

In this independent Chinese MDS cohort, IPSS-M-Evo showed superior prognostic discrimination compared with IPSS-M and IPSS-R and reclassified 58.6% of patients, particularly in the moderate-high to very-high groups. Age provided the largest incremental improvement, particularly for OS, while the evolution-informed molecular component improved LFS discrimination. These findings support the external applicability of IPSS-M-Evo and the value of age adjustment in refining prognostic assessment for MDS.

Yudi Zhang, MD: No relevant conflicts of interest to declare.